Table 2 Results of cost-effectiveness (CE) analyses: incremental effect of genetic screening of MAP families compared to no genetic screening, in different settings:
From: Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations
| Â | Base case | With FOBT* | Heterozygote MUTYH indexpatient |
|---|---|---|---|
Results per child | Â | Â | Â |
   - Additional costs | €470 | €470 | €469 |
   - QALY# gain, discounted | 0.018 years (7 days) | 0.017 years (6 days) | 0.009 years (3 days) |
Results per bi-allelic child | Â | Â | Â |
   - Additional costs | €58,500 | €59,000 | €120,500 |
   - LY†gain, undiscounted | 6.9 years | 6.7 years | 6.9 years |
   - LY gain, discounted | 1.4 years | 1.4 years | 1.4 years |
   - QALY gain, discounted | 2.4 years | 2.3 years | 2.4 years |
Cost effectiveness (in €/LY undiscounted) | 8,500 | 9,000 | 17,500 |
Cost effectiveness (in €/LY discounted) | 42,000 | 42,000 | 86,500 |
Cost effectiveness (in €/QALY discounted) | 25,000 | 25,500 | 51,500 |